PDS BIOTECHNOLOGY CORP
1 day chart
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted immunotherapies for cancer and infectious diseases based on its Versamune, Versamune plus PDS0301, and Infectimune T cell-activating platforms. Its lead clinical candidate, PDS0101, is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a range of HPV16-associated cancers. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment. PDS0102, PDS0103, PDS0104, PDS0201, PDS0202, and PDS0203 are also in its pipeline of Versamune and Infectimune-based therapies.
Buy US stocks in Australia starting with PDSB. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PDSB
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.